对紫杉醇和艾比林过敏？

IF 0.3 4区医学

Revue Francaise d Allergologie Pub Date : 2025-05-20 DOI:10.1016/j.reval.2025.104581

M. Delin , H. Gadoin , E. Ewig , F. Rocher-Moreau , L. Lipszyc , L. Thomas , A. Creisson , B. Gerard , S. Leroy

{"title":"对紫杉醇和艾比林过敏？","authors":"M. Delin , H. Gadoin , E. Ewig , F. Rocher-Moreau , L. Lipszyc , L. Thomas , A. Creisson , B. Gerard , S. Leroy","doi":"10.1016/j.reval.2025.104581","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Eribulin is a drug that is currently used in metastatic breast cancer as an alternative to taxanes. No allergy has been described yet to this molecule.</div></div><div><h3>Patients and methods</h3><div>We described two cases in France that present delayed allergy to eribulin after a first cycle. Both of patients received paclitaxel before.</div></div><div><h3>Results</h3><div>A possible cross-allergy to eribulin with paclitaxel is possible. Our case describes skin testing to eribulin.</div></div><div><h3>Conclusions</h3><div>Cross-allergy between paclitaxel and eribulin is conceivable. This would be a rare undesirable effect, but one that requires particular attention. The mode of action of these two molecules (inhibition of microtubules) could provide a pathophysiological explanation.</div></div>","PeriodicalId":49130,"journal":{"name":"Revue Francaise d Allergologie","volume":"65 5","pages":"Article 104581"},"PeriodicalIF":0.3000,"publicationDate":"2025-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Allergie croisée entre paclitaxel et éribuline ?\",\"authors\":\"M. Delin , H. Gadoin , E. Ewig , F. Rocher-Moreau , L. Lipszyc , L. Thomas , A. Creisson , B. Gerard , S. Leroy\",\"doi\":\"10.1016/j.reval.2025.104581\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><div>Eribulin is a drug that is currently used in metastatic breast cancer as an alternative to taxanes. No allergy has been described yet to this molecule.</div></div><div><h3>Patients and methods</h3><div>We described two cases in France that present delayed allergy to eribulin after a first cycle. Both of patients received paclitaxel before.</div></div><div><h3>Results</h3><div>A possible cross-allergy to eribulin with paclitaxel is possible. Our case describes skin testing to eribulin.</div></div><div><h3>Conclusions</h3><div>Cross-allergy between paclitaxel and eribulin is conceivable. This would be a rare undesirable effect, but one that requires particular attention. The mode of action of these two molecules (inhibition of microtubules) could provide a pathophysiological explanation.</div></div>\",\"PeriodicalId\":49130,\"journal\":{\"name\":\"Revue Francaise d Allergologie\",\"volume\":\"65 5\",\"pages\":\"Article 104581\"},\"PeriodicalIF\":0.3000,\"publicationDate\":\"2025-05-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Revue Francaise d Allergologie\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1877032025003537\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revue Francaise d Allergologie","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1877032025003537","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

黄嘌呤是一种目前用于转移性乳腺癌的药物，作为紫杉烷的替代品。目前还没有人对这种分子过敏。患者和方法我们描述了法国的两个病例，在第一个周期后出现对伊瑞布林的延迟过敏。两例患者均曾接受紫杉醇治疗。结果伊瑞布林与紫杉醇可能存在交叉过敏。我们的病例描述了对伊瑞布林的皮肤试验。结论紫杉醇与伊瑞布林存在交叉过敏。这将是一种罕见的不良影响，但需要特别注意。这两种分子的作用方式（抑制微管）可以提供病理生理学解释。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Allergie croisée entre paclitaxel et éribuline ?

Background

Eribulin is a drug that is currently used in metastatic breast cancer as an alternative to taxanes. No allergy has been described yet to this molecule.

Patients and methods

We described two cases in France that present delayed allergy to eribulin after a first cycle. Both of patients received paclitaxel before.

Results

A possible cross-allergy to eribulin with paclitaxel is possible. Our case describes skin testing to eribulin.

Conclusions

Cross-allergy between paclitaxel and eribulin is conceivable. This would be a rare undesirable effect, but one that requires particular attention. The mode of action of these two molecules (inhibition of microtubules) could provide a pathophysiological explanation.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Revue Francaise d Allergologie Medicine-Immunology and Allergy

自引率

33.30%

发文量

349

期刊介绍： La Revue Française d''Allergologie : un véritable forum pour faire connaître des travaux originaux et permettre la diffusion de l''information auprès de toutes les spécialités concernées par les pathologies allergiques. La Revue Française d''Allergologie (8 numéros par an) est au carrefour de nombreuses spécialités - dermatologie, pédiatrie, ORL, pneumologie, ophtalmologie, médecine interne - qui, toutes, ont à traiter des maladies allergiques. Les symptômes des allergies fondés sur des mécanismes communs sont le plus souvent associés et se succèdent chez un même patient. En forte progression depuis 20 ans, les maladies allergiques sont dans l''attente de perfectionnements et d''avancées thérapeutiques qui permettront aux nombreux patients qui en sont atteints de mieux vivre avec leurs allergies. La Revue Française d''Allergologie se veut donc un véritable forum de discussions et d''échanges entre tous les spécialistes confrontés aux pathologies